IMVT: Immunovant Inc Price to Sales
Immunovant, Inc. (IMVT) maintains business stability by developing specialized treatments for rare pathologies in the US. This historical P/S chart serves as an indicator of market confidence, with recorded as the baseline value. Immunovant, Inc. (IMVT) is developing advanced antibodies for the therapy of immune disorders, aiming to promptly complete final molecule trials prior to the international launch of its products.
Immunovant Corp (IMVT) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- net income and valuation ratios data:
IMVT - Net Profit|Projected Future Earnings Immunovant, Inc.|IMVT - Price to Earnings Ratio|Price to Future Earnings Ratio Immunovant Inc|IMVT - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Immunovant Corp|IMVT - Operating profit before deduction of amortization|Earnings per share for the trailing year Immunovant|IMVT - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months immunovant.com|IMVT - Earnings per share growth in current year|Projected earnings per share growth rate for next year Immunovant, Inc.
- total revenue and sales volume data:
Fundamental company analysis:immunovant.com (IMVT)
The P/S multiple measures the market value of a single ruble of revenue, allowing for an assessment of asset monetization efficiency and the risk of overpaying for a business during a period of stagnant sales. For Immunovant, Inc. (IMVT), whose value is based on the momentum of monoclonal antibody development without current commercial products, the company's rolling P/S reflects market expectations for future trial phases and the issuer's overall financial stability.
Competitors of Immunovant, Inc.
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Price-to-Revenue Coefficient Protagonist Corp PTGX|Kiniksa Pharmaceuticals (KNSA) - Price-to-Revenue Ratio|Market Cap to Revenue grifols.com|Price-to-Revenue Ratio Adaptive Biotechnologies Corporation|Market Cap to Revenue Celldex Therapeutics Inc (CLDX)|Market Cap to Revenue AUPH (Aurinia Pharma)|P/S Multiple BioCryst Corp (BCRX)|Price-to-Revenue Ratio Vera Therapeutics, Inc. VERA|DNTH: Market Cap to Revenue Ratio|PHVS - Price-to-Revenue Ratio|Price to Sales AbCellera Biologics Inc.|TRML (Tourmaline Corp) - Market Cap to Revenue|PGEN (Precigen Corp) - Price-to-Revenue Ratio|PHAR (Pharming Group N.V.) - P/S Multiple|P/S Multiple nektar.com|Price-to-Revenue Ratio Upstream Bio (UPB)|Zenas Bio - Market Cap to Revenue Ratio|Immunome Corp - Market Cap to Revenue|Market Cap to Sales Volume GOSS (Gossamer Bio Corp.)|KALV: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio SEPN (septerna.com)|PVLA: P/S Multiple|SVRA - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Rigel Pharmaceuticals Inc|Market Cap to Revenue Ratio ANAB (AnaptysBio Inc.)|P/S Multiple ATXS|Market Cap to Revenue engene.com ENGN|RAPT Therapeutics - Market Cap to Revenue|Price-to-Revenue Coefficient Aerovate Therapeutics, Inc. (JBIO)|Aclaris - P/S Multiple|Price-to-Revenue Coefficient Kyverna Therapeutics, Inc KYTX|Tiziana Life Sciences (TLSA) - Price-to-Revenue Ratio|Market Cap to Revenue cabalettabio.com|Market Cap to Revenue VTYX|Price-to-Revenue Ratio THTX|Market Cap to Revenue AVTX (Avalo Therapeutics Inc.)|Market Cap to Sales Volume ELDN|Price-to-Revenue Ratio Agenus AGEN|CLYM (climbbio.com) - Price-to-Sales Ratio|Zura Bio - P/S Multiple|Market Capitalization-to-Revenue Ratio ATYR (aTyr Pharma Inc)|ADAG: P/S Multiple|Ikena Oncology (IMA) - P/S Multiple|Price-to-Revenue Ratio Shattuck Labs Inc|EQ: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Connect Biopharma (CNTB)|Market Cap to Revenue immunic-therapeutics.com IMUX|P/S Multiple ATRA (Atara Bio)|P/S Multiple InflaRx NV IFRX|XFOR: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACET (Adicet Bio)|CELU: P/S Multiple|INMB - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Barinthus Bio|Market Cap to Revenue Kezar Life Sciences Inc (KZR)|Price-to-Revenue Ratio SAB Biotherapeutics (SABS)|Market Cap to Revenue akaritx.com AKTX|Enlivex Therapeutics Ltd. - Market Cap to Revenue|P/S Multiple Q32 Bio Inc QTTB|GOVX - Price-to-Revenue Ratio|EDSA (Edesa Biotech Corp) - Market Cap to Revenue Ratio|IBIO: P/S Multiple|Price to Sales Carisma Therapeutics Inc. (CARM)|XTLB (XTL Biopharmaceuticals Ltd.) - P/S Multiple|Bolt Bio (BOLT) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|Market Cap to Revenue aptevotherapeutics.com APVO|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|ADTX - Market Cap to Revenue|GRI: Market Cap to Revenue|XRTX - P/S Multiple|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio REVB|Price-to-Revenue Ratio Indaptus Therapeutics|Price to Sales scinai.com SCNI|Market Cap to Revenue CALI (CalciMedica, Inc.)|Price-to-Revenue Ratio AFMD (affimed.com)|P/S Multiple ALLK (Allakos)|P/S Multiple HOOKIPA Pharma, Inc. HOOK|IGMS - Price-to-Revenue Ratio|ITOS (iteostherapeutics.com) - Market Cap to Revenue Ratio|OCEA (Ocean Biomedical) - Market Cap to Revenue|TCBP: Market Cap to Sales Volume|Market Cap to Revenue THRD
